-
Drug Maker In Pressure: Merck & Co., Inc. (NYSE:MRK) Face Lawsuit of $100 million
A sales person for Merck & Co., Inc. (NYSE:MRK) filed court case of overi$100M sex discrimination against the drugmaker, asserting that it mainly distinguishes alongside pregnant employees and women among children. In a claim filed in U.S. District Court in New Jersey, the claimant, Kelli Smith asserts she was downgraded for taking maternity leave in…
-
Merck & Co., Inc. (NYSE:MRK) to Appoint Roger Perlmutter Research Head, Barclays PLC (ADR) (NYSE:BCS) Upgraded the Company to Buy
The renowned pharmaceutical firm Merck & Co., Inc. (NYSE:MRK) recently declared that it is appointing the Amgen retired research chief at its own research division. The division is currently being headed by Peter Kim and after his planned retirement Roger Perlmutter will take his position at Merck. Some of the most successful products of Merck…